HHS. 2008 (November). Draft Strategic National Vaccine Plan. Available: http://www.hhs.gov/nvpo/vacc_plan/2008plan/draftvaccineplan.pdf [accessed December 2008].
IAVI (International AIDS Vaccine Initiative). 2009. The PDP Model. Available: http://www.iavi.org/Research-Development/Preparing-The-Market/Pages/Product-Development-Partnerships.aspx [accessed September 17, 2009].
IOM (Institute of Medicine). 2007. Global Infectious Disease Surveillance and Detection: Assessing the Challenges—Finding Solutions: Workshop Summary. Washington, DC: The National Academies Press.
IOM. 2009a. Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies: Workshop Summary. Washington, DC: The National Academies Press.
IOM. 2009b. The U.S. Commitment to Global Health: Recommendations for the Public and Private Sectors. Washington, DC: The National Academies Press.
IOM. 2009c (June 1). Transcript, Fifth National Stakeholder Meeting of the IOM Committee on Review of Priorities in the National Vaccine Plan. Seattle, Washington: IOM.
Kamara, L., J.B. Milstien, M. Patyna, P. Lydon, A. Levin, and L. Brenzel. 2008. Strategies for financial sustainability of immunization programs: A review of the strategies from 50 national immunization program financial sustainability plans. Vaccine 26(51):6717-6726.
Kieny, M.P., and M.P. Girard. 2005. Human vaccine research and development: An overview. Vaccine 23(50):5705-5707.
LaForce, M., and W. Perea. 2008. Conquering Epidemic Meningitis in Africa: Introducing a Men A Conjugate Vaccine. Meningitis Vaccine Project. Available: http://www.gavialliance.org/resources/17_Meningitis.ppt [accessed October 6, 2009].
Letourneau, M., G. Wells, W. Walop, and P. Duclos. 2008. Improving global monitoring of vaccine safety: A quantitative analysis of adverse event reports in the WHO adverse reactions database. Vaccine 26(9):1185-1194.
Levine, O.S., T. Cherian, R. Hajjeh, and M. Deloria Knoll. 2009. Progress and future challenges in coordinated surveillance and detection of pneumococcal and Hib disease in developing countries. Clin Infect Dis 48(s2):S33-S36.
Lieu, T.A., T.G. McGuire, and A.R. Hinman. 2005. Overcoming economic barriers to the optimal use of vaccines. Health Aff 24(3):666-679.
Lydon, P., A. Jones, and L. Kamara. 2007 (April 17). Changing Context of Immunization Financing—Issues For Future Immunization Efforts. Presentation at the Strategic Advisory Group of Experts on Immunization Financing Meeting. Varembé, Geneva: World Health Organization.
Mahmoud, A. 2005. The vaccine enterprise: Time to act. Health Aff 24(3):596-597.
Milstien, J.B., M. Kaddar, and M.P. Kieny. 2006. The impact of globalization on vaccine development and availability. Health Aff 25(4):1061-1069.
NVAC (National Vaccine Advisory Committee). 1997. United States vaccine research: A delicate fabric of public and private collaboration. Pediatrics 100(6):1015-1020.
PATH (Program for Appropriate Technology in Health). 2009. Meningitis Vaccine Project: Timeline. Available: http://www.meningvax.org/timeline.htm [accessed October 6, 2009].
Plahte, J. 2005. Tiered pricing of vaccines: A win-win-win situation, not a subsidy. Lancet Infect Dis 5(1):58-63.
PneumoADIP. 2009. Hib Vaccines. Available: http://www.pneumoadip.org/vaccine_status/hib_vaccines/index.cfm [accessed October 5, 2009].
Oxfam. 2008. Ending the R&D crisis in public health: Promoting pro-poor medical innovation. Oxfam Briefing Paper:122.
Reingold, A.L., C.V. Broome, A.W. Hightower, G.W. Ajello, G.A. Bolan, and C. Adamsbaum. 1985. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 2:114-118.